NASDAQ:ETONEton Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eton Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.74 +0.06 (+0.90 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$6.70Now: $6.74▼$7.1550-Day Range$4.96MA: $5.65▼$6.6852-Week Range$2.50Now: $6.74▼$7.70Volume632,161 shsAverage Volume196,944 shsMarket Capitalization$141.00 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Eton Pharmaceuticals has a potential upside of 107.7% from its current price of $6.74.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesEton Pharmaceuticals has received 66 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEton Pharmaceuticals has received 72 “underperform” votes. (Add your “underperform” vote.)Community SentimentEton Pharmaceuticals has received 52.17% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eton Pharmaceuticals and other stocks. Vote “Outperform” if you believe ETON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ETON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.92% of the stock of Eton Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 28.54% of the stock of Eton Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($1.30) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 11.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETON Previous Symbol CUSIPN/A CIKN/A Webwww.etonpharma.com Phone847-787-7361Debt Debt-to-Equity Ratio0.43 Current Ratio7.48 Quick Ratio6.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$460,000.00 Price / Sales306.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book11.42Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-18,320,000.00 Net MarginsN/A Return on Equity-158.98% Return on Assets-120.85%Miscellaneous Employees15 Outstanding Shares20,920,000Market Cap$141.00 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable $6.74 +0.06 (+0.90 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ETON News and Ratings via Email Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions How has Eton Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ETON shares have increased by 60.5% and is now trading at $6.74. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eton Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eton Pharmaceuticals. When is Eton Pharmaceuticals' next earnings date? Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Eton Pharmaceuticals. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals Inc (NASDAQ:ETON) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.28. The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $1.62 million. View Eton Pharmaceuticals' earnings history. What price target have analysts set for ETON? 3 brokerages have issued twelve-month price targets for Eton Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Eton Pharmaceuticals' stock price to reach $14.00 in the next year. This suggests a possible upside of 107.7% from the stock's current price. View analysts' price targets for Eton Pharmaceuticals. Has Eton Pharmaceuticals been receiving favorable news coverage? News articles about ETON stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Eton Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Eton Pharmaceuticals. Are investors shorting Eton Pharmaceuticals? Eton Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 750,200 shares, an increase of 33.1% from the June 30th total of 563,500 shares. Based on an average trading volume of 129,700 shares, the days-to-cover ratio is currently 5.8 days. Currently, 5.3% of the shares of the company are sold short. View Eton Pharmaceuticals' Current Options Chain. Who are some of Eton Pharmaceuticals' key competitors? Some companies that are related to Eton Pharmaceuticals include Vanda Pharmaceuticals (VNDA), G1 Therapeutics (GTHX), Legend Biotech (CALT), Emisphere Technologies (EMIS), Collegium Pharmaceutical (COLL), Cue Biopharma (CUE), Viking Therapeutics (VKTX), RAPT Therapeutics (RAPT), Flexion Therapeutics (FLXN), Syndax Pharmaceuticals (SNDX), Provention Bio (PRVB), Athersys (ATHX), TherapeuticsMD (TXMD), Ardelyx (ARDX) and Molecular Templates (MTEM). View all competitors. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Agile Therapeutics (AGRX), Amarin (AMRN), Myovant Sciences (MYOV), Anavex Life Sciences (AVXL), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Intra-Cellular Therapies (ITCI) and Micron Technology (MU). Who are Eton Pharmaceuticals' key executives? Eton Pharmaceuticals' management team includes the following people: Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64) When did Eton Pharmaceuticals IPO? (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. What is Eton Pharmaceuticals' stock symbol? Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON." Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Westside Investment Management Inc. (0.39%), First Trust Advisors LP (0.13%) and UBS Group AG (0.02%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View institutional ownership trends for Eton Pharmaceuticals. Which institutional investors are selling Eton Pharmaceuticals stock? ETON stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Eton Pharmaceuticals. Which institutional investors are buying Eton Pharmaceuticals stock? ETON stock was bought by a variety of institutional investors in the last quarter, including Westside Investment Management Inc., and First Trust Advisors LP. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Sean Brynjelsen, and William Wilson Troutman. View insider buying and selling activity for Eton Pharmaceuticals. How do I buy shares of Eton Pharmaceuticals? Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eton Pharmaceuticals' stock price today? One share of ETON stock can currently be purchased for approximately $6.74. How big of a company is Eton Pharmaceuticals? Eton Pharmaceuticals has a market capitalization of $141.00 million and generates $460,000.00 in revenue each year. The company earns $-18,320,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe. What is Eton Pharmaceuticals' official website? The official website for Eton Pharmaceuticals is www.etonpharma.com. How can I contact Eton Pharmaceuticals? Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
